Pope Francis to Undergo Intestinal Surgery Under General Anesthesia 

Pope Francis reacts as he meets faithful during the weekly general audience in St. Peter's Square at the Vatican, June 7, 2023. (Reuters)
Pope Francis reacts as he meets faithful during the weekly general audience in St. Peter's Square at the Vatican, June 7, 2023. (Reuters)
TT

Pope Francis to Undergo Intestinal Surgery Under General Anesthesia 

Pope Francis reacts as he meets faithful during the weekly general audience in St. Peter's Square at the Vatican, June 7, 2023. (Reuters)
Pope Francis reacts as he meets faithful during the weekly general audience in St. Peter's Square at the Vatican, June 7, 2023. (Reuters)

Pope Francis went to the hospital Wednesday to undergo abdominal surgery to treat an intestinal blockage, two years after he had 33 centimeters (13 inches) of his colon removed because of a narrowing of the large intestine.

The Vatican said Francis, 86, would be put under general anesthesia for the procedure Wednesday afternoon and would be hospitalized at Rome's Gemelli hospital for several days.

Francis' Fiat 500 car pulled out of the Vatican shortly after 11 a.m. with an escort, and arrived at the Gemelli some 20 minutes later.

The pope is undergoing what the Vatican said was a "laparotomy and abdominal wall plastic surgery with prosthesis" to treat a "recurrent, painful and worsening" constriction of the intestine.

A laparotomy is open abdominal surgery. It can help a surgeon both diagnose and treat issues. The statement said Francis was suffering from a blocked laparocele, which is a hernia that formed over a previous scar.

"The stay at the health facility will last several days to allow for the normal post-operative course and full functional recovery," the statement said. An update was not expected until after the procedure.

Francis remains in charge of the Vatican and the 1.3-billion strong Catholic Church, even while unconscious and in the hospital.

In July 2021, Francis spent 10 days at Gemelli to remove 33 centimeters (13 inches) of his large intestine. He had suffered what the Vatican said was a severe inflammation and narrowing of the colon. In an interview with The Associated Press in January, Francis said the diverticulosis, or bulges in his intestinal wall, that had prompted the 2021 surgery, had returned.

Francis had come out of the 2021 surgery saying he could eat whatever he wanted, but he lamented that he hadn’t responded well to the general anesthetic used in the longer-than-expected procedure. That reaction in part explained his refusal to have surgery to repair strained knee ligaments that have forced him to use a wheelchair and walker for over a year.

The fact that he is going back for surgery suggests he had little choice but to treat the intestinal issue, especially given the rigorous upcoming travel schedule this summer.

The Argentine pope had part of one lung removed when he was a young man. He also suffers from sciatica nerve pain. In late March, Francis spent three days at Gemelli for an acute case of bronchitis, during which he was treated with intravenous antibiotics. He emerged April 1 saying "Still alive!"

Francis initially went to the Gemelli on Tuesday for what the Vatican said were medical tests. It revealed no details at the time.

The 86-year-old had appeared in good form Wednesday morning at his audience in St. Peter’s Square, zipping around the square in his popemobile greeting the faithful. He also had two meetings beforehand, the Vatican said.

Francis has had a packed schedule of late, with multiple audiences each day. The Vatican has recently confirmed a travel-filled August, when the Holy See and Italy are usually on vacation, with a four-day visit to Portugal the first week of August and a similarly long trip to Mongolia starting Aug. 31.

In a sign that the trips were very much on, the Vatican on Tuesday released the planned itinerary for Francis’ visit to Portugal for World Youth Day events from Aug. 2-6. The itinerary confirms a typically busy schedule that includes all the protocol meetings of an official state visit plus multiple events with young people.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”